Trastuzumab, an anti-ErbB2 antibody, and lapatinib, a small-molecule inhibitor of ErbB2/epidermal growth factor receptor (EGFR), are used for treatment of ErbB2-positive cancers [3, 4]. This evidence concerns the gene ERBB2 and cancer.